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Abstract:  
 
Context 
Patients’ preference for morphine therapy has received little attention in the setting of 
chronic refractory breathlessness. However, this is one important factor in considering 
longer term therapy. 
 
Objectives 
 The aim of this secondary analysis is to explore blinded patient preference of morphine 
compared to placebo for this indication and to define any predictors of preference. 
 
Methods 
Data were pooled from three randomized, double-blind, cross-over, placebo-controlled 
studies of morphine (4 days each) in chronic refractory breathlessness. Blinded patient 
preferences were chosen at the end of each study. A multivariable regression model was 
used to establish patient predictors of preference. 
 
Results 
Sixty-five participants provided sufficient data (60 males; median age 74 years; heart 
failure 55%, COPD 45%; median ECOG 2). Forty-three percent of participants pre-
ferred morphine (32% placebo and 25% no preference).  
 
Morphine preference and younger age were strongly associated: OR = 0.85 (CI = 0.78, 
0.93; p<0.001). There was also an inverse association between morphine preference and 
sedation OR = 0.77 (CI = 0.60, 0.99; p<0.05). An inverse association was also seen be-
tween nausea and morphine preference in the univariate model only (p<0.05). No asso-
ciation was seen between morphine preference and breathlessness intensity, either at 
baseline or change from baseline. 
 
Conclusion 
Participants preferred morphine over placebo for the relief of chronic refractory breath-
lessness.  Morphine offers clinically important improvement but net benefit can be easi-
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ly outweighed by side-effects reducing net benefits. Side-effects require aggressive 
management to allow more patients to realise benefits.  
 
Keywords:  patient preference, palliative care, breathlessness, COPD, morphine, ran-
domized controlled trial  
 
Running title: Blinded patient opioid preference in dyspnoea 
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Introduction: 
Persistent breathlessness despite optimal medical therapy and a person’s own adaptation 
(refractory breathlessness), is prevalent in people with advanced disease.1 Such refracto-
ry breathlessness is multifactorial, influenced by physical, psychosocial and spiritual 
factors.2 
 
Studies have demonstrated encouraging results for the safe use of opioids for reducing 
chronic refractory breathlessness.3-7 A secondary pooled analysis of three randomized, 
double-blind, cross-over studies revealed that younger age and higher baseline breath-
lessness were predictors of greater likelihood of response to opioid therapy whereas 
functional status and aetiology were not.8 Further, analysis of this pooled dataset found 
that a difference of only 9mm on a 0-100mm visual analogue scale (VAS) was suffi-
cient for a participant to prefer one treatment arm over another.  
 
Patient preferences for an intervention are derived from the net benefit - that is, patients’ 
perceived balance of benefits and side-effects. A better understanding of preferences 
may allow insight to improve individually tailored prescribing for refractory breathless-
ness. Factors not yet identified could also influence the net clinical effects in patients’ 
perceived response, impacting on choice and ongoing compliance. 
 
The aim of this study was to explore blinded patient preferences for morphine or place-
bo for chronic refractory breathlessness from data pooled from the only three double-
blind, cross-over, randomised controlled trials (RCTs) performed in this setting4-6 – two 
adequately powered to detect a minimally clinically important difference (MCID)4,5,9 
and one pilot study.6  
 
Methods: 
Design: Ninety-three participants with refractory breathlessness, defined as that which 
persists despite optimum treatment of the underlying condition,5were included in these 
studies. Inclusion criteria in this pooled analysis included completion of the cross-over 
trial and availability of blinded patient preference for the arm of the study which they 
felt provided better benefit for breathlessness. In the Oxberry et al study patients were 
randomised to morphine, oxycodone or placebo.4 To optimize comparability in the 
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analysis, patients whose blinded preference relied on oxycodone were excluded (n=9). 
Almost all participants had heart failure (HF; n=36) or chronic obstructive pulmonary 
disease (COPD; n=29). Two patients had other aetiologies (restrictive lung disease 
(n=1) and cancer (n=1)) and were also excluded leaving 65 participants (Figure 1). Data 
were already anonymised. Ethics confirmed that permission was not required for analy-
sis of pooled, anonymised data, where appropriate written informed consent had been 
obtained for each participant. 
 
Methods: Measurements of breathlessness before and after 4 days of morphine 
(20mg/day or 10 mg/day if creatinine > 200 µmol/L (n=2)), and placebo were collected, 
seeking to define the effect of morphine on refractory breathlessness. The studies’ 
methods are described in detail elsewhere, including the rationale for combining 
measures of breathlessness intensity and performance status.4,5,6  
 
Study participants: Participants had chronic refractory breathlessness. Baseline partici-
pant characteristics collected by all included studies were age, gender, disease aetiolo-
gy, breathlessness intensity and functional status.  
 
Scale measurements: Numerical Rating Scale (NRS) were converted to Visual Ana-
logue Scales (VAS) as patients’ reporting have similar distributions10,11 and thus NRS 
scores were represented as equivalent 0/100 in the pooled data. For the functional status, 
New York Heat Association (NYHA) was converted to Karnofsky Performance Scale 
(KPS)12 and all measures using KPS were converted to Eastern Cooperative Oncology 
Group performance scale (ECOG).13 For toxicity, qualitative outcomes were used due to 
heterogeneity in the scales used.  
 
Statistical analysis:  
Anova or Kruskall-Wallis tests compared differences between groups for covariates that 
were normally and non-normally distributed respectively. Chi-square tests compared 
proportions for categorical variables between groups. The primary outcome, morphine 
preference, is trichotomous: morphine preference; preference for placebo or no prefer-
ence. Multivariable ordinal logistic regression assessed associations between morphine 
preference and age, performance status (ECOG), disease aetiology (HF vs COPD), 
baseline breathlessness, improvement in breathlessness, nausea, sedation and constipa-
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tion. Improvement in these four symptoms was defined as the change in each attribute 
over the morphine study period minus the change in each attribute over the placebo pe-
riod. The proportional odds assumption was examined (using Stata’s brant command) 
and no evidence of model violation was found (p=0.66). Results are presented with 95% 
confidence intervals and a p-value of less than 0.05 (two-sided) is considered statistical-
ly significant. All analyses were performed with Stata 13.1, (StataCorp, Texas, USA).  
 
Results: 
 
Baseline data from each study are presented in Table 1. Changes in breathlessness 
achieved in each study are described in Table 2. The combined dataset yielded a popula-
tion with a mean (sd) age of 71.6 (9.8) years of whom 60 were male. (Table 1) Disease 
aetiology for breathlessness was HF (55%) and COPD (45%). The median ECOG was 2 
(Ambulatory and capable of all self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours) and the median (IQR) baseline breathlessness was 
48mm (30 to 60) indicating moderately intense breathlessness.  
 
Data from 28 participants were excluded or missing (Figure 1) with 11 participants not 
completing the cross-over, and missing blinded preference data in 6 participants. A rela-
tive predominance of the excluded subjects were females but otherwise clinic and de-
mographic characteristics were similar between the two groups. 
 
Preference: Twenty-eight participants (43.1%) preferred morphine, 21 (32.3%) placebo 
and 16 (24.6%) had no preference. For the patients who stated preference, median 
breathlessness improvement is presented in Figure 2.  
 
Predictors of preference: In multivariable analysis, there was a strong association be-
tween morphine preference and younger age (OR = 0.85 (CI = 0.78, 0.93; p<0.001); 
Table 3). There was also an inverse association between morphine preference and seda-
tion (OR = 0.77 (CI = 0.60, 0.99; p<0,05)). An inverse association was seen between 
nausea and morphine preference in the univariate model only (p<0.05). No association 
was seen between morphine preference and breathlessness intensity, either at baseline 
or change from baseline. 
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Fifty-five percent of the patients with HF preferred morphine compared to 28% of peo-
ple on COPD although this was not statistically significance (OR = 0.50 (95% CI = 
0.07, 3.38); p=0.48). Only one study provided information on sleep quality5. None of 
the patients whose sleep quality improved on morphine showed a preference for this 
drug and so this was not included in regression modelling. 
 
Analysis was conducted exploring three adverse effects on morphine preference. There 
was no multivariate association between blinded patient preference and nausea 
(p=0.25), although in the univariate analysis those experiencing nausea were less likely 
to prefer morphine (p=0.049). No association between constipation and blinded patient 
preference was evident (Table 3).  
 
Discussion: 
This secondary analysis showed that younger age is an important factor in opioid pref-
erence for the relief of refractory breathlessness when compared with placebo. Addi-
tionally, there is an inverse relationship between the side-effects of sedation and nausea, 
and morphine preference, which suggests that these side-effects can easily outweigh any 
benefits obtained.  
 
Younger age: Younger age is correlated with patient preference. One observation in this 
dataset that may help to explain this difference is that there was a lower frequency of 
nausea in younger participants (13% under 70 and 26% over 70 years old). A sub-group 
analysis to determine the predictors of preference amongst younger participants was not 
conducted since there were insufficient participants to conduct a thorough statistical 
analysis. Additionally, it is possible that an opioid-related reduction of sympathetic 
drive may be more effective in younger people which may relate to some dimensions 
commonly associated with breathlessness. Future studies could explore this sub-group 
in more detail. 
 
Disease aetiology: The proportion of participants who preferred morphine was notably 
higher in heart failure than COPD. Extensive work has been conducted on the role of 
opioids in the relief of breathlessness. Central opioid receptor pathways seem to be aeti-
ology independent,14 much discussion is still ongoing regarding the role of different 
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aetiology-specific peripheral pathways for breathlessness.15 Future work should address 
this issue in more detail. 
 
Baseline breathlessness intensity and clinical response: On an individual level, it would 
appear that higher clinical response rates may lead to higher morphine preference 
rates.4,6 In this set of data, baseline breathlessness intensity did not correlate with blind-
ed patient preference. This finding was unexpected since previous work has shown that 
higher values of baseline breathlessness were predictors of response to opioid therapy.8 
Nevertheless, morphine reduces but does not eliminate breathlessness and the presence 
of undesirable side effects seems to have a clear impact on patients’ choice, outweigh-
ing any clinical benefit obtained.  
  
Other measures such as the affective component of breathlessness (the unpleasantness 
of breathlessness) may help to explain why more people, while still blinded, chose mor-
phine than the other options. None of these studies included an affective measure.  
 
Functional status: No correlation was found between baseline functional status and 
blinded patients’ preference. The studies did not measure physical functioning, either 
for activities of daily living or physical activity, during or at the end of participation. 
Patients may continue to exert themselves to the same level of breathlessness so that 
they may feel that their breathlessness has not changed while on morphine although 
they are more active. Intensity of breathlessness may ultimately improve but only over 
time as skeletal muscles and sympathetic activity respond to improved conditioning.16,17 
Therefore, it is likely that these studies have not captured all the patient-relevant bene-
fits. 
 
Alternatively, a lower functional status can predispose patients to a higher degree of 
immobility which could be thought to reduce breathlessness and exacerbate other ad-
verse symptoms such as constipation.  
 
Adverse Effects: There were inverse relationships between blinded morphine preference 
and separately sedation and nausea. Constipation did not seem to play a significant role 
in morphine preference. On the whole, patients’ preference for morphine seems to be 
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hindered by the occurrence of side effects, at times possibly overshadowing any direct 
effect on the relief of breathlessness.  
 
Previous studies have analysed patient preference in several fields of medicine with 
conclusive evidence that medication efficacy and even symptom control are sometimes 
secondary when compared to medication induced side effects.19,20 Some studies also 
reached the conclusion that lack of sedation or nausea is particularly important when 
preferring or adhering to one therapy over another.20-22 In the setting of pain control, the 
importance of side effects has also been noted.23,24,25 
 
The minimally clinically important difference (MCID) in chronic breathlessness is 
smaller when compared to acute breathlessness with the implication that any harms, 
toxicities or side-effects may have greater impact on patient preference in chronic 
breathlessness.9,26 This highlights that side effects should be carefully addressed and 
aggressively handled which ultimately might improve the rates of a perceived net clini-
cal benefit, best expressed by patients’ blinded preference and, ultimately, long term 
compliance with medications.  
 
These data included three short term studies with a cross over design. As it is known, 
unwanted side effects are most strongly noted in the first days of morphine treatment 
and often preventive medication is required. In these studies, drugs like anti-emetics or 
laxatives were not regularly used. As such, the first four days of therapy may not be 
representative of longer term therapy.  
 
Quality of sleep: Previous studies have shown improvement in quality of sleep in other 
clinical contexts, at the appropriate morphine dosages.27 None of these studies however 
focused on morphine preference. Only one of the initial studies analysed herein includ-
ed data on sleep quality,5 but participants in this study who reported decreased breath-
lessness whilst taking morphine were also likely to report improved sleep quality with 
morphine (p=0.039). Despite an improvement in sleep quality in the morphine arm, this 
was not a factor in determining morphine preference.  
 
Strengths of the study: To our knowledge, this was the first study evaluating blinded 
patient preference for morphine in the setting of chronic refractory breathlessness, alt-
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hough previous analysis of this pooled dataset has investigated the clinical improvement 
in breathlessness intensity required for patients to choose one treatment arm over anoth-
er irrespective of final choice.9 This parameter has been largely under-evaluated while 
there is evidence to show that patient preference and lack of adverse effects is often 
associated with compliance22,28,29 and, possibly, clinical outcomes.  
 
Limitations: This was a post-hoc (secondary) analysis conducted on three studies. Two 
of these studies were adequately powered and one was a pilot. This was an exploratory, 
hypothesis generating study. The main aim thus was to provide a basis for future re-
search.  
 
The study conducted by Oxberry et al had three arms (morphine, oxycodone and place-
bo). The patients that preferred oxycodone were excluded from the analysis. Apart from 
making the data more comparable, as previously stated, there is significant controversy 
on the role different opioids play in the relief of breathlessness.30 Further adequately 
powered studies are necessary to shed light into this topic. 
 
Measuring breathlessness constitutes a challenge. The most commonly used measure-
ment scales in both clinical practice and research rely solely on uni-dimensional meas-
urement of breathlessness intensity. Given the multi-dimensional nature of this symp-
tom, it is easy to miss important benefits obtained with morphine treatment. In addition, 
a similar issue applies to unidimensional measurements of other symptoms such as nau-
sea and sedation, such as the measurement used in these studies. This unidimensional 
assessment of side-effects might also miss important features that may significantly 
influence patients’ preference.  
 
Furthermore, in order to analyse breathlessness scores, functional status and adverse 
effects, it was necessary to achieve common outcome measures, converting different 
scales. This could have had an impact in the obtained results. 
 
Sample: The studies analysed contained a predominance of male subjects. The relative 
proportion of female subjects who did not complete the cross-over was higher than their 
male counterparts. The opioid trial period was of 4 days and it could be that were ad-
verse events such as nausea and sedation treated more aggressively as opioids were ini-
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tiated, there could have been more completions, especially as these symptoms often 
completely resolve soon after opioids are initiated. Longer term data are needed to an-
swer this question. In terms of aetiology, the analysis is limited to participants with 
COPD and heart failure.  
 
Clinical implications: This study analysed blinded participants’ preferences rather than 
the stated primary outcome. In fact, there was no significant direct association between 
change in breathlessness intensity and blinded morphine preference. This highlights the 
need to consider patients’ perceived net benefit when initiating a therapy including 
whether level of function improves. The occurrence of side-effects should be actively 
monitored and aggressively treated. Routine enquiry about other important patient-
relevant outcomes such as perceived breathlessness unpleasantness and exercise toler-
ance may help assess whether opioids have provided net clinical benefit. 
 
Unanswered questions and future directions: Adequately powered randomized, double 
blind studies should be performed to address the issues concerning predictors of prefer-
ence. Also, predictors of side effects and the ways to prevent them should be addressed, 
since they seem to be a key factor in influencing blinded patients’ preference. This work 
also outlines the need to include other measures of breathlessness, such as the affective 
component associated and an objective measure of physical activity and function. This 
could explain the apparent lack of correlation between morphine preference and clinical 
response. Given the age related asymmetries of clinical response and preference for 
opioid therapies, sub-group analysis of younger and older patients should be considered 
in future studies.  
 
These data included three short term studies. Longer term studies using morphine may 
help to determine if side effects have the same impact on patients’ preference.  
  
Conclusions 
In this study, participants preferred morphine over placebo for the relief of chronic re-
fractory breathlessness. Morphine offers clinically important improvement but net bene-
fit is easily outweighed by side-effects reducing overall preference. Side-effects require 
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aggressive management to allow more patients to realise benefits.  Single, unidimen-
sional measures of breathlessness may miss key benefits of therapy 
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Table 1 – Characteristics of the 65 participants who provided data on opioid or placebo 
preferencechoice for chronic refractory breathlessness.  
Variables Johnson et al. Abernethy et al. Oxberry et al. 
P‐value for 
difference 
  n=10 n=29 n=26  
Age (years), 
median (IQ 25‐75) 66.2 (11.6)  75.8 (5.1) 69.1 (11.4) 0.005 
  Male gender, n(%) 10 (100) 26 (89.6) 24 (92.3) 0.84
HF disease†, n (%) 10 (100) 0 (0) 26 (100) <0.001 
   Intensity of baseline breathlessness, 
median (IQ 25‐75) 46.5 (14.3‐58.0) 46.0 (30.0‐60.0) 50.0 (30.0‐60.0) <0.001 
ECOG , n(%)       0.002 
   ECOG 1 0 (0) 9 (31.0) 5 (19.2)  
   ECOG 2 10 (100) 13 (44.8) 21 (80.8)  
   ECOG 3 and 4 0 (0) 7 (24.1) 0 (0)  
† HD vs. COPD     
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Table 2 – Improvement in chronic refractory breathlessness and blinded patients pref-
erence for morphine. 
  Baseline breathlessness 
Absolute breathlessness im‐
provement 
Pts that preferred Mor‐
phine (%) 
Study Median (IQ range) Median (IQ range)   
Johnson et al 
(N=10) 46.5 (14.25 to 58) 18 (2.75 to 38.25) 6 (60%) 
Abernethy et al 
(N=29) 46 (30 to 60) 0 (‐12 to 17) 8 (27.6%) 
Oxberry et al 
(Morphine arm) 
(N=26) 50 (30 to 60) 10 (0 to 12.5) 14 (53.8%) 
Combined 48 (30 to 60) 9 (‐1.5 to 20) 28 (43.1%) 
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Table 3: Associations between morphine preference and variables from pooled data of 
three randomised, double-blind, placebo controlled cross over studies of morphine for 
refractory breathlessness. 
 Univariable Multivariable‡ 
Breathlessness  (95% CI)  (95% CI)
Gender   2.07 (0.34, 12.54) 2.95 0.30, 28.85)  
Age 0.88 (0.81, 0.94)*** 0.85 0.78, 0.93)*** 
Aetiology of breathlessness 0.55 (0.22, 1.36) 0.46 (0.07, 3.18) 
Improvement in breathlessness of day 4 over 0.99 (0.98, 1.01) 1.00 (0.98, 1.02) 
Baseline breathlessness 1.00 (0.98, 1.01) 1.00 (0.97, 1.03) 
Nausea 0.82 (0.68, 1.00)* 0.84 (0.97, 1.03) 
Sedation 0.92 (0.76, 1.11) 0.77 (0.60, 0.99)* 
Constipation 1.58 (0.62, 4.04) 1.61 (0.42, 9.16) 
Eastern Cooperative Oncology Group performance scale
 2 0.49 (0.19, 1.32) 0.24 (0.04,1.43) 
 3 0.77 (0.17, 3.50) 1.00 (0.11, 9.13) 
 
 
p<0.05 *, p < 0.01**, p<0.001*** 
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Fig 1 – Diagram concerning the selection of patients for this study.. 
  
 
 
 
  
10 Patients completed the 
cross-over 
37 Patients completed the 
cross-over
35 Patients completed the 
cross-over
Johnson et al. 
10 Patients analyzed 
Abernethy et al. 
48 patients analyzed
Oxberry et al. 
35 Patients analyzed
6 Patients with 
missing blinded 
preference data 
11 Patients did not 
complete the cross-
over
9 Patients with 
Oxycodone prefer-
ence
65 Patients were analyzed 
1 Patient had Cancer 
and 1 Patient had Re-
strictive Lung Disease 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2 - Variation in median breathlessness intensity (baseline and conclusion) with pla-
cebo and morphine.  
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